Dupilumab을 투여받은 아토피성 피부염이 있는 6세 이상의 프랑스 참가자에 대한 장기 데이터 수집 연구 (DUPILAB)
아토피성 피부염에 대해 Dupilumab을 투여받은 환자에 대한 프랑스의 전향적 관찰 연구.
This is a long-term study to collect data over 3 years in order to find out what is likely to happen in the future regarding participants 6 years of age and older who receive dupilumab for Atopic Dermatitis (AD) commonly known as Eczema, and to characterize real-world effectiveness, safety and use patterns of dupilumab in real world setting in France. Patients will be invited to participate if initiating treatment with dupilumab for AD according to French-specific prescribing information. The decision of initiation of the treatment is independent to the study's participation. The study will be conducted in approximately 50 centers in France to evaluate a representative sample of patients treated in France. At each participating site, all AD participants who receive an initial prescription for dupilumab will be invited to participate in this study, until the enrollment goal is achieved.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (실제)
등록
연락처 및 위치
연구 장소
-
-
-
Amiens, 프랑스, 80054
- Investigational Site Number: 2500041
-
Angers, 프랑스, 49000
- Investigational Site Number: 2500037
-
Argenteuil, 프랑스, 95107
- Investigational Site Number: 2500021
-
Armentières, 프랑스, 59280
- Investigational Site Number: 2500044
-
Arras, 프랑스, 62000
- Investigational Site Number: 2500018
-
Ars-Laquenexy, 프랑스, 57530
- Investigational Site Number: 2500011
-
Avignon, 프랑스, 84000
- Investigational Site Number: 2500023
-
Besançon, 프랑스, 25000
- Investigational Site Number: 2500001
-
Bron, 프랑스, 69500
- Investigational Site Number: 2500003
-
Caen, 프랑스, 14033
- Investigational Site Number: 2500043
-
Chambéry, 프랑스, 73000
- Investigational Site Number: 2500050
-
Clermont-Ferrand, 프랑스, 63113
- Investigational Site Number: 2500006
-
Dijon, 프랑스, 21231
- Investigational Site Number: 2500005
-
Epagny Metz Tessy, 프랑스, 74370
- Investigational Site Number: 2500004
-
Fort-de-France, 프랑스, 97261
- Investigational Site Number: 2500039
-
La Tronche, 프랑스, 38700
- Investigational Site Number: 2500045
-
Le Havre, 프랑스, 76083
- Investigational Site Number: 2500019
-
Le Mans, 프랑스, 72037
- Investigational Site Number: 2500040
-
Les Sables-d'Olonne, 프랑스, 85100
- Investigational Site Number: 2500038
-
Levallois-Perret, 프랑스, 92300
- Investigational Site Number: 2500048
-
Lille, 프랑스, 59037
- Investigational Site Number: 2500032
-
Limoges, 프랑스, 87000
- Investigational Site Number: 2500002
-
Lorient, 프랑스, 56100
- Investigational Site Number: 2500036
-
Marseille, 프랑스, 13008
- Investigational Site Number: 2500029
-
Montpellier, 프랑스, 34090
- Investigational Site Number: 2500028
-
Nantes, 프랑스, 44093
- Investigational Site Number: 2500024
-
Nice, 프랑스, 06000
- Investigational Site Number: 2500025
-
Nice, 프랑스, 6300
- Investigational Site Number: 2500020
-
Pau, 프랑스, 64000
- Investigational Site Number: 2500016
-
Poitiers, 프랑스, 86000
- Investigational Site Number: 2500042
-
Pontoise, 프랑스, 95300
- Investigational Site Number: 2500022
-
Périgueux, 프랑스, 24019
- Investigational Site Number: 2500009
-
Romans-sur-Isère, 프랑스, 26102
- Investigational Site Number: 2500014
-
Rouen, 프랑스, 76031
- Investigational Site Number: 2500008
-
Saint-Germain-en-Laye, 프랑스, 78100
- Investigational Site Number: 2500015
-
Saint-Mandé, 프랑스, 94163
- Investigational Site Number: 2500027
-
Saint-Nazaire, 프랑스, 44606
- Investigational Site Number: 2500026
-
Saint-Pierre, 프랑스, 97410
- Investigational Site Number: 2500035
-
Saint-Pierre, 프랑스, 97448
- Investigational Site Number: 2500013
-
Toulouse, 프랑스, 31059
- Investigational Site Number: 2500012
-
Valence, 프랑스, 26000
- Investigational Site Number: 2500010
-
Vandœuvre-lès-Nancy, 프랑스, 54500
- Investigational Site Number: 2500031
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
The population of interest for this study will be patients in France aged 6 years old or more with a diagnosis of AD either severe or moderate to severe (depending on age group) who initiate dupilumab in real world setting. The study will be conducted in real conditions of practice, dupilumab will be prescribed at the sole initiative of the participating physician irrespective of patient enrolment decision.
설명
Inclusion Criteria:
- Male or female, 6 years or older.
- Initiating treatment with dupilumab for AD according to French-specific prescribing information (≥ 12 years old: moderate to severe AD versus 6-11 years old: severe AD). The decision of initiation of the treatment is independent to the study's participation.
- Able to understand and complete study-related questionnaires.
- Signed informed consent form. For participants <18 years old, Informed consent form signed by the parent/legal guardian and participant's assent obtained.
Exclusion Criteria:
- Patients who have a contraindication to the drug according to the French-specific prescribing information label.
- Any condition that, in the opinion of the Investigator, may interfere with patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from adequately completing, as per routine care, the schedule of visits and assessments.
- Patients currently participating in any interventional clinical trial.
- Patients previously treated with dupilumab.
- Patients under tutorship or curatorship; patients under safeguard of justice or deprived of his/her liberty by an administrative or court decision.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
Participants with AD treated with dupilumab
Patients ≥6 years of age in whom dupilumab therapy was initiated to treat their AD according to French-specific prescribing information. |
Dupilumab cohort
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
AD 치료를 위해 두필루맙을 투여받은 참가자의 체중 특성
기간: 기준선에서
|
기준선에서
|
|
|
AD 치료를 위해 두필루맙을 투여받은 참가자의 신장 특성
기간: 기준선에서
|
기준선에서
|
|
|
동반질환 및 치료는 기준치에서 변경됩니다.
기간: 기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
|
기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
|
|
|
아토피 동반질환 및 치료는 기준치와 달라졌습니다.
기간: 기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
|
기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
|
|
|
두필루맙 용량의 기준선 대비 변화
기간: 기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
|
기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
|
|
|
두필루맙 투여의 기준선 대비 변화
기간: 기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
|
기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
|
|
|
치료에 대한 두필루맙 순응도의 기준선 대비 변화
기간: 기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
|
기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
|
|
|
두필루맙 임시 또는 영구 중단 시 기준선 대비 변화
기간: 기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
|
기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
|
|
|
두필루맙 치료의 기준선에서 다른 치료법으로 전환
기간: 기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
|
기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
|
|
|
병용 AD 치료에 대한 두필루맙 치료의 기준선 대비 변화
기간: 기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
|
기준선에서는 3개월, 6개월, 12개월, 18개월, 24개월, 30개월, 36개월
|
|
|
Demographic characteristics of participants who receive dupilumab for AD
기간: At baseline
|
Including age, gender, educational level, socio-professional category |
At baseline
|
|
Medical history characteristics of participants who receive dupilumab for AD
기간: At baseline
|
including previous treatments for AD, relevant medical history, family history of atopy |
At baseline
|
|
Change from baseline in lifestyle habits of participants who receive dupilumab for AD
기간: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36 if applicable
|
Including alcohol, tobacco, CBD and cannabis consumption |
At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36 if applicable
|
|
Change in patient's treatment satisfaction score using the Patient Global Assessment of Treatment Effect (PGATE)
기간: At month 6, month 12, month 18, month 24, month 30, month 36
|
PGATE for patients ≥ 12 years of age: an internally developed and validated instrument allowing patients to rate their opinion and perceived treatment effect. Ratings are on a 5-point Likert scale from 1 being "Poor" and 5 being "Excellent". |
At month 6, month 12, month 18, month 24, month 30, month 36
|
|
Change in eczema severity using the Eczema Area and Severity Index (EASI)
기간: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
EASI is a validated measure used to assess severity and extent of AD at each body region by multiplying the lesions characteristics score x the body area score x multiplier. Four AD disease characteristics -erythema, thickness (induration, population, and oedema), scratching (excoriation), and lichenification - will each be assessed for severity by the observing physician, as follows: 0 = none, absent; 1=mild (just perceptible); 2=Moderate (obvious); 3=Severe. The area score ranges from 0 to 6 is determined as follows: 0= 0% (no active eczema in region); 1= 1-9%; 2= 10-29%; 3= 30-49%; 4= 50-69%; 5= 70-89%; 6= 90-100% (entire region affected by eczema). The multiplier is determined according to the region affected and the age of the patient: 0.1 or 0.2 for patients < 8 years old (head/neck), 0.2 (upper limbs), 0.3 (trunk), 0.4 or 0.3 for patients < 8 years old (lower limbs). A higher score means higher AD severity. Scores range from 0 (no disease) to 72 (maximal disease severity). |
At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
|
Change in AD disease control using the Atopic Dermatitis Control Tool (ADCT)
기간: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
ADCT for patients aged ≥ 12 years of age: a validated, brief and easily scored tool consisting of six concise questions allowing to rate the different dimensions of patient-perceived AD control, to foster communication between patients and their physicians and help appropriate decision-making. The instrument includes 6 items, with a 7-day recall period: overall severity of symptoms, frequency of intense episodes of itching, severity of bother, frequency of sleep impact, severity of daily activities impact and severity of mood or emotions impact. Each item is rated on a 5-point Likert scale, ranging from 0 (none/ not at all/ no nights) to 4 (very severe/ everyday/ extremely/ every night); the total score ranges from 0 to 24, which is the summation of the responses to all the items. A total score of ≥7 points was derived as the threshold to identify patients "not in control", based on optimal sensitivity/ specificity values. The higher the score, the less AD is controlled. |
At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
|
Change in itch assessment
기간: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
Itch assessment (Worst-Itch Numeric Rating Scale, WI-NRS) will be rated from 0 to 10 on average during the past 7 days (adult, pediatric and adolescent patients), completed by the observing physician after questioning of patient; 0 = no itch and 10 = the worst imaginable itch. |
At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
|
Change in sleep disturbance NRS
기간: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
NRS sleep disturbance will be rated from 0 to 10 on average during the past 7 days (adult, pediatric and adolescent patients), completed by the observing physician after questioning of patient; 0 = "sleep not disturbed at all" (best possible sleep) and 10 = "sleep extremely disturbed (worst possible sleep)". |
At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
|
Change in global patient's disease evaluation using the Patient Global Assessment of Disease Severity (PGADS)
기간: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
PGADS for patients ≥ 12 years of age: an internally developed and validated instrument allowing to the patients to rate their AD-related overall well-being. Patients will be asked: "Considering all the ways in which your eczema affects you, how well are you doing?" Response choices will be from 1 being "Poor" to 5 being "Excellent". |
At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
|
Change in global patient's disease evaluation using the Caregiver Global Assessment of Disease (CGAD)
기간: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
CGAD for patients 6 to 11 years of age: an internally developed and validated instrument allowing to the caregivers to rate their child's AD-related overall well-being. Caregivers will be asked: "Considering all the way in which the eczema affects your child, how well is your child doing?". Response choices will be 1 being "Poor" to 5 being "Excellent". |
At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
|
Change in Dermatology Life Quality Index (DLQI)
기간: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
DLQI for patients ≥ 16 years (or cDLQI for patients < 16 at baseline) are 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life in adults and pediatrics, respectively. The format is a simple response (0 to 3 where 0 is "not at all" and 3 is "very much") to 10 items, which assess quality of life over the past week, with an overall scoring system of 0 to 30; a high score is indicative of a poor quality of life. Patients 6-11 years old will be assisted for questionnaire completion. A cDLQI's cartoon version could be also used for patients from 6 to 11 years old. If a patient turns 16 years old during the study, they will switch to DLQI. |
At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
|
Change in Dermatitis Family Impact Questionnaire (DFI)
기간: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
DFI is a 10-item, validated questionnaire assessing the impact of AD on the QoL of the parents/legal representatives and family members of affected children. The format is a simple response (0 to 3 where 0 is "not at all" and 3 is "very much") to 10 items, which assess Quality of Life (QoL) over the past week, with an overall scoring system of 0 to 30; a high score is indicative of a poor QoL. It is designed to be completed by adults (aged 16 years or over) who have a child (up to and including the age of 15 years 11 months) in the family with atopic dermatitis. |
At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
|
Change in European Quality of Life-5 Dimensions-3 level score (EQ-5D-3L)
기간: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
The EQ-5D-3L is completed by patients≥18 years old and by parent/legal representative of patients<18 years old. It consists of 2 parts:
|
At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
|
Change in Work Productivity and Activity Impairment Questionnaire, Atopic Dermatitis (WPAI-AD)
기간: At month 6, month 12, month 18, month 24, month 30, month 36
|
WPAI-AD for adults and WPAI-CIQ-AD for adolescents is a questionnaire designed to assess the impact of AD on the patient's productivity. The WPAI-AD is the version of the original generic WPAI that is specific to AD. It is a 6-item, validated questionnaire to measure impairments in work and activities over a 7-day recall period. The WPAI-AD outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. If a patient turns 18 years old during the study, this one will switch to WPAI-AD. |
At month 6, month 12, month 18, month 24, month 30, month 36
|
|
Number of Adverse Events (AE)
기간: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
AEs for dupilumab and/or concomitant treatments will be collected throughout the study. |
At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
|
Change from baseline in Drug Survival
기간: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
Drug survival is defined as the time from the start of treatment to the end or discontinuation of treatment with no changes. If a patient has multiple drug survival events for the same treatment, the longest drug survival will be used in the data summarization. The drug survival will be illustrated using a Kaplan-Meier plot. |
At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
공동 작업자 및 조사자
협력자
협력자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- OBS17668
- U1111-1279-3469 (레지스트리 식별자: ICTRP)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .